Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report.

Literature DB >> 18710781

The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report.

Joshua P Kesterson¹, Paulette Mhawech-Fauceglia, Shashikant Lele.

Abstract

BACKGROUND: The potential role of bevacizumab in the treatment of ovarian granulosa-cell tumors has not been evaluated. CASE: An 82 year old woman with refractory ovarian granulosa-cell carcinoma was treated with bevacizumab with symptomatic relief of ascites.
CONCLUSION: Bevacizumab may have a role in the management of malignant ascites in the patient with refractory granulosa-cell carcinoma of the ovary which should be confirmed in a larger series of well selected patients.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2008 PMID： 18710781 PMCID： PMC5047386 DOI： 10.1016/j.ygyno.2008.07.015

Source DB: PubMed Journal: Gynecol Oncol ISSN： 0090-8258 Impact factor: 5.482

9 in total

1. The role of bevacizumab in ovarian cancer--an evolving story.

Authors: Carol Aghajanian
Journal: Gynecol Oncol Date: 2006-08 Impact factor: 5.482

2. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer.

Authors: Bradley J Monk; Ernest Han; Carol A Josephs-Cowan; Gordon Pugmire; Robert A Burger
Journal: Gynecol Oncol Date: 2006-06-21 Impact factor: 5.482

3. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma.

Authors: T Michael Numnum; Rodney P Rocconi; Jenny Whitworth; Mack N Barnes
Journal: Gynecol Oncol Date: 2006-06-23 Impact factor: 5.482

4. Vascular endothelial growth factor is a secreted angiogenic mitogen.

Authors: D W Leung; G Cachianes; W J Kuang; D V Goeddel; N Ferrara
Journal: Science Date: 1989-12-08 Impact factor: 47.728

5. Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line.

Authors: Kohkichi Hata; Mitsuhiko Osaki; Dipok Kumar Dhar; Kentaro Nakayama; Ritsuto Fujiwaki; Hisao Ito; Naofumi Nagasue; Kohji Miyazaki
Journal: Cancer Chemother Pharmacol Date: 2003-10-21 Impact factor: 3.333

6. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

Authors: Stephen A Cannistra; Ursula A Matulonis; Richard T Penson; Julie Hambleton; Jakob Dupont; Howard Mackey; Jeffrey Douglas; Robert A Burger; Deborah Armstrong; Robert Wenham; William McGuire
Journal: J Clin Oncol Date: 2007-11-20 Impact factor: 44.544

7. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Authors: Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky
Journal: J Clin Oncol Date: 2007-11-20 Impact factor: 44.544

8. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer.

Authors: David E Cohn; Sue Valmadre; Kimberly E Resnick; Lynne A Eaton; Larry J Copeland; Jeffrey M Fowler
Journal: Gynecol Oncol Date: 2006-03-09 Impact factor: 5.482

9. Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF.

Authors: Melanie Schmidt; Ulrike Kammerer; Sabine Segerer; Andreas Cramer; Nico Kohrenhagen; Johannes Dietl; Hans-Ullrich Voelker
Journal: Eur J Obstet Gynecol Reprod Biol Date: 2008-04-03 Impact factor: 2.435

9 in total

1. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.

Authors: Markus M Heiss; Pawel Murawa; Piotr Koralewski; Elzbieta Kutarska; Olena O Kolesnik; Vladimir V Ivanchenko; Alexander S Dudnichenko; Birute Aleknaviciene; Arturas Razbadauskas; Martin Gore; Elena Ganea-Motan; Tudor Ciuleanu; Pauline Wimberger; Alexander Schmittel; Barbara Schmalfeldt; Alexander Burges; Carsten Bokemeyer; Horst Lindhofer; Angelika Lahr; Simon L Parsons
Journal: Int J Cancer Date: 2010-11-01 Impact factor: 7.396

Review 2. Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review.

Authors: Filippo Bellati; Chiara Napoletano; Ilary Ruscito; Maria Pastore; Milena Pernice; Morena Antonilli; Marianna Nuti; Pierluigi Benedetti Panici
Journal: Invest New Drugs Date: 2009-11-24 Impact factor: 3.850

Review 3. Recent advances in granulosa cell tumor ovary: a review.

Authors: Vijaykumar Dehannathparambil Kottarathil; Michelle Aline Antony; Indu R Nair; Keechilat Pavithran
Journal: Indian J Surg Oncol Date: 2012-12-07

4. Anti-VEGFA Therapy Reduces Tumor Growth and Extends Survival in a Murine Model of Ovarian Granulosa Cell Tumor.

Authors: Mayra Tsoi; Marie-Noëlle Laguë; Alexandre Boyer; Marilène Paquet; Marie-Ève Nadeau; Derek Boerboom
Journal: Transl Oncol Date: 2013-06-01 Impact factor: 4.243

Review 5. The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.

Authors: Michael Bradshaw; Aaron Mansfield; Tobias Peikert
Journal: Curr Oncol Rep Date: 2013-06 Impact factor: 5.075

9. Clinical efficacy of endostar combined with chemotherapy in the treatment of peritoneal carcinomatosis in gastric cancer: results from a retrospective study.

Authors: Jing Yao; Li Fan; Chunfen Peng; Ai Huang; Tao Liu; Zhenyu Lin; Qin Yang; Tao Zhang; Hong Ma
Journal: Oncotarget Date: 2017-08-07

9 in total

The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report.

1. The role of bevacizumab in ovarian cancer--an evolving story.

2. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer.

3. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma.

4. Vascular endothelial growth factor is a secreted angiogenic mitogen.

5. Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line.

6. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

7. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

8. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer.

9. Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF.

1. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.

Review 2. Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review.

Review 3. Recent advances in granulosa cell tumor ovary: a review.

4. Anti-VEGFA Therapy Reduces Tumor Growth and Extends Survival in a Murine Model of Ovarian Granulosa Cell Tumor.

Review 5. The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.

6. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors.

Review 7. Monoclonal antibodies in gynecological cancer: a critical point of view.

8. Emerging treatment options for management of malignant ascites in patients with ovarian cancer.

9. Clinical efficacy of endostar combined with chemotherapy in the treatment of peritoneal carcinomatosis in gastric cancer: results from a retrospective study.